Autolus Therapeutics (AUTL) Net Margin (2017 - 2026)
Autolus Therapeutics' (AUTL) quarterly Net Margin came in at 372.02% in Q4 2025, up 9482108.0% YoY from N/an in Q4 2024, and little changed on a QoQ basis from 373.3% in Q3 2025.
Autolus Therapeutics (AUTL) Net Margin (2017 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 9 years of Net Margin data on file, last reported at 372.02% in Q4 2025.
- Quarterly Net Margin rose 9482108.0% year-over-year to 372.02% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 381.43% (up 179708.0% YoY) and the FY2025 annual result came in at 381.43%, up 179902.0% from the prior year.
- Net Margin was little changed at 372.02% in Q4 2025, from 373.3% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 229.02% in Q2 2025 to a low of 95193.1% in Q4 2024.
- A 5-year average of 11834.6% and a median of 2003.27% in 2021 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin tumbled 995996 bps — and 2025, when it soared 9482108 bps.
- Tracing AUTL's Net Margin over 5 years: stood at 14402.97% in 2021, then surged by 95 bps to 737.33% in 2022, then plunged by 1432 bps to 11292.86% in 2023, then slumped by 743 bps to 95193.1% in 2024, then soared by 100 bps to 372.02% in 2025.
- The last three Net Margin figures came in at 372.02% (Q4 2025), 373.3% (Q3 2025), and 229.02% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn | -85.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -85.60% |
| Dec 31, 2025 | -372.02% |
| Sep 30, 2025 | -373.30% |
| Jun 30, 2025 | -229.02% |
| Mar 31, 2025 | -781.13% |
| Dec 31, 2024 | -95,193.10% |
| Mar 31, 2024 | -521.68% |
| Sep 30, 2023 | -11,292.86% |
| Mar 31, 2023 | -3,081.35% |
| Dec 31, 2022 | -737.33% |
| Sep 30, 2022 | -1,805.28% |
| Mar 31, 2022 | -22,326.51% |
| Sep 30, 2021 | -14,402.97% |
| Jun 30, 2021 | -2,201.26% |
| Mar 31, 2021 | -12,366.54% |
| Dec 31, 2020 | -10,604.46% |
| Sep 30, 2020 | -8,511.42% |
| Jun 30, 2020 | -10,936.86% |
| Mar 31, 2020 | -8,836.98% |
| Jun 30, 2019 | -2,417.51% |